ArticleCommunications medicine2026

Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial.

Xiaolu Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.